NCT03193918View on ClinicalTrials.gov

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 14, 2017

Primary Completion Date

July 15, 2020

Study Completion Date

July 15, 2020

Conditions
Esophagogastric Adenocarcinoma
Interventions
DRUG

Crenolanib

Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg

DRUG

Ramucirumab

Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days

DRUG

Paclitaxel

Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
lead

Arog Pharmaceuticals, Inc.

INDUSTRY